EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised NeoRecormon (epoetin beta) from Roche Registration GmbH for multiple indications, including chronic kidney disease–related anemia, other form…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• NeoRecormon (epoetin beta)

Snippet

Status: Authorised. Therapeutic area: Kidney Failure, Chronic;Anemia;Cancer;Blood Transfusion, Autologous. MAH: Roche Registration GmbH. Decision date: 01/05/2025